Arcellx Newsroom

Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial

Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.

Zhitong FinanceMay 16 09:10 ET

Arcellx Is Maintained at Buy by Stifel

Arcellx Is Maintained at Buy by Stifel

Dow JonesMay 15 06:58 ET

Express News | Arcellx Inc : Stifel Raises Target Price to $83 From $82

ReutersMay 15 06:37 ET

Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

TipRanksMay 14 10:05 ET

Analyst Expectations For Arcellx's Future

During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, she

BenzingaMay 14 08:01 ET

Arcellx Initiated at Outperform by Evercore ISI Group

Arcellx Initiated at Outperform by Evercore ISI Group

Dow JonesMay 14 05:29 ET

Buy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market Positioning

TipRanksMay 14 04:46 ET

Express News | Arcellx Inc : Evercore ISI Initiates Coverage With Outperform Rating; Price Target $85

ReutersMay 14 01:51 ET

Arcellx Is Maintained at Buy by HC Wainwright & Co.

Arcellx Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 13 13:50 ET

Express News | HC Wainwright & Co. Maintains Buy on Arcellx, Lowers Price Target to $80

BenzingaMay 13 13:41 ET

Buy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic Partnerships

TipRanksMay 13 03:15 ET

Arcellx, Inc. (NASDAQ:ACLX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its quarterly report and things are looking bullish. The results were impressive, with revenues of US$39m exceeding analyst forecasts by 90%, and statuto

Simply Wall StMay 12 10:03 ET

Arcellx First Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceMay 12 08:49 ET

Express News | Needham Reiterates Buy on Arcellx, Maintains $81 Price Target

BenzingaMay 10 15:29 ET

Arcellx Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 64.42% Needham → $81 Reiterates Buy → Buy 05/07/2024 64.42% Needham → $81 Reiterates Buy → Buy

BenzingaMay 10 15:28 ET

Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge

Yahoo FinanceMay 10 13:13 ET

Express News | Arcellx Shares Are Trading Lower After the Company Reported Q1 Financial Results

BenzingaMay 10 10:26 ET

Buy Rating Affirmed for Arcellx Inc on Robust IMMagine-3 Study Prospects and Efficient Manufacturing

TipRanksMay 10 08:18 ET

Buy Rating Justified for Arcellx Inc. Amidst Progress in Anito-cel's Clinical Development and Regulatory Milestones

TipRanksMay 10 06:26 ET

Express News | Arcellx, Inc. : H.c. Wainwright Cuts Target Price to $80 From $82

ReutersMay 10 06:10 ET